Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Adjuvant Durvalumab (MEDI4736) Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial

NCT05382741 is registered in ClinicalTrials.gov with Ospedale Policlinico San Martino as lead sponsor.

NCT NCT05382741
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05382741 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Adjuvant Durvalumab (MEDI4736) Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
Lead sponsor
Ospedale Policlinico San Martino
Phase
Phase 2
Overall status
Unknown status
Start date
March 2, 2022
Completion date
March 2, 2024
Enrollment
182 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer stage iv, no evidence of disease state